Disclosures for "A Phase 1a/b Open Label Study of SAT-3247 in Healthy Volunteers and Adult Patients with Duchenne Muscular Dystrophy"
-
Dr. Farwell has received personal compensation for serving as an employee of Dyne Therapeutics. Dr. Farwell has received personal compensation for serving as an employee of Satellos Biosciences. Dr. Farwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Paragon Therapeutics. Dr. Farwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. Dr. Farwell has stock in Dyne Therapeutics. Dr. Farwell has stock in Satellos Bioscience.
-
Dr. Dubow has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revalesio .
-
Ms. Wells has received personal compensation for serving as an employee of Satellos Bioscience, Inc.. Ms. Wells has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for HSG. Ms. Wells has stock in Satellos Bioscience, Inc.. Ms. Wells has stock in Tourmaline.
-
Dr. Lambert has received personal compensation for serving as an employee of Satellos Bioscience. Dr. Lambert has stock in Satellos Bioscience. Dr. Lambert has received intellectual property interests from a discovery or technology relating to health care.
-
Dr. Mitchell has received personal compensation for serving as an employee of Satellos Bioscience.